Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest Cataplexy Stories

2012-09-12 14:22:30

In the news release, Jazz Pharmaceuticals Announces Issuance of New Formulation Patent for Xyrem®, issued 11-Sep-2012 by Jazz Pharmaceuticals over PR Newswire, we are advised by the company that the first paragraph, second sentence, should read "8,263,650" rather than "8,262,650" as originally issued inadvertently. The complete, corrected release follows: Jazz Pharmaceuticals Announces Issuance of New Formulation Patent for Xyrem® DUBLIN, Sept. 11, 2012 /PRNewswire/ --...

2012-07-30 02:25:46

Awards to Researchers at Harvard, Stanford and Toronto's Hospital for Sick Children WORCESTER, Mass., July 30, 2012 /PRNewswire-USNewswire/ -- Wake Up Narcolepsy, Inc. (WUN), a nonprofit dedicated to broadening awareness of narcolepsy and accelerating the pace of medical discovery in the disorder, recently made research grants totaling $40,000 to three world-leading scientific investigators. The awardees are: Dr. Emmanuel Mignot, director of the Center for Sleep...

2012-07-23 02:25:23

Raising Awareness of a Devastating but Under-diagnosed Illness WORCESTER, Mass., July 23, 2012 /PRNewswire-USNewswire/ -- Wake Up Narcolepsy (WUN) (wakeupnarcolepsy.org), a nonprofit organization dedicated to raising awareness of narcolepsy and finding a cure for this debilitating, lifelong condition, today announced that Kenneth McDonnell, of Holden, MA, has joined WUN as vice president of marketing and community relations. Narcolepsy is a neurological disease that affects some...

2012-06-11 10:24:24

DUBLIN, June 11, 2012 /PRNewswire/ -- A survey of narcolepsy awareness conducted in the United States and released today by Jazz Pharmaceuticals (Nasdaq: JAZZ) confirms that while the majority of Americans view sleep as highly important, only half (50%) believe narcolepsy can significantly impact overall health, despite evidence that symptoms of this serious sleep disorder can be severe enough to disrupt a person's social, personal and professional life and limit their activities.(1) Findings...

2012-04-03 02:23:51

Harvard Neuroscientist joins international runners to raise awareness and research funds for narcolepsy WORCESTER, Mass., April 3, 2012 /PRNewswire-USNewswire/ -- Six Wake Up Narcolepsy (WUN) supporters will run the Boston Marathon on April 16, 2012 to raise awareness and funds for cutting-edge narcolepsy research. Runners include a Harvard-affiliated neuroscientist, Nancy Chamberlin, who is a sleep expert and researcher. A portion of funds raised will support the world-renowned...

2011-09-08 20:50:09

Narcolepsy is a rare disorder characterized by an excessive urge to sleep at inappropriate times and places. Narcoleptics are also often subject to "cataplexy," a sudden muscle weakness that is triggered by strong emotions. Although most cases of narcolepsy are thought to be caused by complex mechanisms, a small percentage of cases are associated with unidentified inherited mutations. Now, a new study published by Cell Press on September 8th in the American Journal of Human Genetics uncovers...

2011-04-22 00:00:28

The Cohen Foundation is a non-profit organization in North Carolina, based in the Mecklenburg County area, that provides education to families and Communities of Children diagnosed with Narcolepsy with Cataplexy, Support Groups, support in obtaining a cure for Narcolepsy and provides financial relief towards medical expenses for families of children with diagnosis. Charlotte, NC (PRWEB) April 21, 2011 The Cohen Foundation, Inc. has been instituted to find a cure for Narcolepsy and...

2010-10-20 07:00:00

SAN DIEGO, Oct. 20, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today results from a Phase 1 clinical trial of APD916, a novel drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy with cataplexy. The randomized, double-blind and placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of 1 mg, 3 mg and 5 mg single doses of APD916. The trial evaluated 24 healthy volunteers...

2010-03-24 07:00:00

SAN DIEGO, March 24, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy and cataplexy. "There is a need for better tolerated, more effective therapies for narcolepsy, especially narcolepsy with cataplexy," said William R. Shanahan, M.D., Arena's Vice President...

2010-02-16 08:48:30

Individuals with the sleep disorder narcolepsy suffer with excessive daytime sleepiness and attacks of muscle paralysis triggered by strong emotions (a condition known as cataplexy). It is thought that narcolepsy is an autoimmune disorder "” that is, it is caused by the individual's immune system attacking certain cells in the body "” but this has not yet been proven definitively. However, Mehdi Tafti and colleagues, at the University of Lausanne, Switzerland, have now identified...